IR (Infrared) fluctuated by 102.3% in 24 hours: trading volume surge drives intense volatility
Bitget Pulse2026/04/29 22:03Brief Overview of Volatility
In the past 24 hours, the price of IR soared from a low of $0.01713 to a high of $0.03465, and is currently at $0.02055, marking a fluctuation range of 102.3%. Trading volume surged significantly, reaching $3.92 million to $5.57 million within 24 hours, which is 3 to 5 times higher than usual.
Analysis of Reasons Behind the Unusual Movement
- Surging Trading Volume: According to Bitget data, IR experienced 24-hour volatility of 100.9%, mainly driven by a spike in trading volume, with no official announcements or records of large on-chain whale transfers.
- Short-term Momentum: Monitoring on X platform shows abnormal buying activity and volume spikes (e.g., 2.8x-3.7x) driving the price pump, but there are no clear news events.
Market Opinions and Outlook
The trading community sentiment is mainly cautiously optimistic. AI signals (such as Finora) regard this as a momentum-driven pump, recommending to wait for a pullback to the $0.027-$0.030 demand zone before going long, with a target of $0.035, but warning of bull trap risks and possible quick reversals; the overall outlook depends on sustained trading activity, and no mainstream analysts have issued long-term forecasts.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
Crypto prices
More
